As they do every summer, publicly traded companies posted their second-quarter results while Americans were baring their bodies on the beach.
But this year, the timing was apt.
On several earnings calls in August, chief executives reassured investors that the Ozempic revolution had not left them in the dust, and that they could somehow share in the blazing success of new diabetes and weight loss drugs.
“We will continue to study this,” Michael Johnson, the chief executive of the nutritional supplement maker Herbalife, told investors.
“And when we see an opportunity to capitalize on it, we will.”In theory, that opportunity — both for making profits and for losing fortunes — could be vast not only for the companies behind these drugs but also for some in completely different industries.
Persons:
baring, ”, Dan R, “, ” Michael Johnson, —
Locations:
Chard